demonstrated that Apigenin triggers apoptosis in Primary effusion lymphoma (PEL) cells, suppressing the activation of AKT/PKB pathway via downregulating Skp2, hypo-phosphorylation of Rb, and accumulating p27Kip1 expression levels, which suggest that Apigenin may possibly have future therapeutic potential in PEL (74). The gene discussed is SKP2; the disease is primary effusion lymphoma.